Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
NCT05036135 · Aerovate Therapeutics · PHASE2/PHASE3 · terminated · last registry update 2024-08-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.” | – | Registry record, Aerovate Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GRIN1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-28Phase 3 first posted: Università Vita-Salute San Raffaele, Ketamine Hydrochloride + Placebo (NCT07088380)
- 2025-06-06Results posted on the registry: NRG Oncology, Memantine (NCT04588246)
- 2025-04-02Phase 3 first posted: University of Virginia, Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET) + Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET) (NCT06907173)
- 2025-03-24Phase 3 first posted: The Royal's Institute of Mental Health Research, ketamine hydrochloride (NCT06891300)
- 2025-02-19Phase 3 first posted: Columbia University, Ketamine hydrochloride + Morphine sulphate (NCT06835504)
- 2025-01-17Phase 3 first posted: Sunnybrook Health Sciences Centre, Ketamine (NCT06781697)
- 2025-01-09Phase 3 first posted: McMaster University, ketamine hydrochloride (NCT06767358)
- 2024-12-31Phase 3 first posted: Theresa Jacob, PhD, MPH, nebulized ketamine + nebulized midazolam (NCT06752759)
- 2024-12-03Phase 3 first posted: Yale University, Racemic ketamine + Spravato (Esketamine) (NCT06713616)
- 2024-06-18Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Morphine + IN fentanyl (NCT06464146)
- 2024-05-24Phase 3 first posted: Dr George Medvedev, Eptinezumab (NCT06428838)
- 2024-04-10Results posted on the registry: Washington University School of Medicine, Ketamine + Normal saline (NCT05233566)
- 2023-09-22Phase 3 first posted: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Fentanyl Citrate + Esketamine (NCT06051227)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision